Literature DB >> 22178574

The association of antiphospholipid antibodies with intrauterine fetal death: a case-control study.

Linda Björk Helgadottir1, Finn Egil Skjeldestad, Anne Flem Jacobsen, Per Morten Sandset, Eva-Marie Jacobsen.   

Abstract

INTRODUCTION: Over the past few decades it has been recognized that antiphospholipid antibodies are associated with pregnancy loss. Other placenta-mediated pregnancy complications have also been associated with the presence of antiphospholipid antibodies. Most studies have measured antiphospholipid antibodies near the time of the event investigated.
OBJECTIVES: To investigate the association of antiphospholipid antibodies and a history of intrauterine fetal death (IUFD) in a case-control design.
MATERIALS AND METHODS: A case-control study of 105 women with a history of IUFD after 22 gestational weeks and 262 controls with live births. The prevalence of lupus anticoagulant, anticardiolipin- and anti-β2-glycoprotein 1 antibodies were measured 3-18years after the event of IUFD.
RESULTS: Total 9.5% of women with a history of IUFD and 5.0% of controls had at least one positive test for antiphospholipid antibodies (OR 2.0; 95% confidence interval (CI) 0.9-4.8). Women with a history of IUFD were significantly more often positive for lupus anticoagulant compared to controls (OR 4.3; 95% CI 1.0-18.4). The association of lupus anticoagulant with a history of IUFD was confined to women positive for other antiphospholipid antibodies in addition to lupus anticoagulant. Being positive for anti-β2-glycoprotein 1 or anticardiolipin antibodies alone was not significantly associated with a history of IUFD.
CONCLUSIONS: Women with a history of IUFD after 22 gestational weeks were more often lupus anticoagulant positive. The association was confined to women with multiple positivity for antiphospholipid antibodies, although firm conclusions on the importance of multiple positivity cannot be made from this study.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22178574     DOI: 10.1016/j.thromres.2011.11.029

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  What's new in obstetric antiphospholipid syndrome.

Authors:  D Ware Branch
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant.

Authors:  Johanna Gebhart; Florian Posch; Silvia Koder; Peter Quehenberger; Thomas Perkmann; Lorenz Kuessel; Cihan Ay; Ingrid Pabinger
Journal:  Blood Adv       Date:  2019-03-12

3.  Intrauterine fetal deaths related to antiphospholipid syndrome: a descriptive study of 65 women.

Authors:  Mériem Belhocine; Laetitia Coutte; Nicolas Martin Silva; Nathalie Morel; Gaëlle Guettrot-Imbert; Romain Paule; Claire Le Jeunne; Micaela Fredi; Michel Dreyfus; Jean-Charles Piette; Odile Souchaud-Debouverie; Catherine Deneux-Tharaux; Vassilis Tsatsaris; Emmanuelle Pannier; Véronique Le Guern; Nathalie Costedoat-Chalumeau
Journal:  Arthritis Res Ther       Date:  2018-11-06       Impact factor: 5.156

Review 4.  Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review.

Authors:  Jaume Alijotas-Reig; Enrique Esteve-Valverde; Ariadna Anunciación-Llunell; Joana Marques-Soares; Josep Pardos-Gea; Francesc Miró-Mur
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

5.  Hypernephroma presenting with cutaneous leukocytoclastic vasculitis and lupus anticoagulant: resolution after nephrectomy.

Authors:  Nigel P Murray; Amparo Ruíz; Eduardo Reyes
Journal:  Case Rep Urol       Date:  2012-08-07

6.  Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results.

Authors:  Cecile M Yelnik; Carl A Laskin; T Flint Porter; D Ware Branch; Jill P Buyon; Marta M Guerra; Michael D Lockshin; Michelle Petri; Joan T Merrill; Lisa R Sammaritano; Mimi Y Kim; Jane E Salmon
Journal:  Lupus Sci Med       Date:  2016-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.